Compare Cintas Corporation (CTAS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Medpace Holdings Inc — how do they compare? Cintas Corporation trades at $204.05 (market cap $82.15B), while Medpace Holdings Inc trades at $599.22 (market cap $16.90B). The key difference: Cintas Corporation is far larger — about 4.9× Medpace Holdings Inc's market cap, and Cintas Corporation pays a 1.01% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| CTAS | MEDP | |
|---|---|---|
Market Cap | $82.15B | $16.90B |
Sector | Industrials | Technology |
52-Week High | $225.10 | $620.59 |
52-Week Low | $163.55 | $393.42 |
Enterprise Value | $84.56B | $16.52B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $204.86, up 1.06% on the day, with a bullish technical signal and recent earnings beats driving positive momentum. The company reported strong Q2 2026 EPS of $1.29, exceeding expectations, and maintains robust fundamentals with a 17.75% net income margin and 40.59% ROE. Revenue growth is steady, reaching $10.34B in 2025, supported by consistent profitability and a dividend payout.
The outlook is positive, with a consensus price target of $225.83 implying ~10% upside, though high valuation ratios (P/E 41.81) and competitive pressures pose risks. Institutional interest is strong, with recent upgrades, but investors should monitor debt levels and economic sensitivity.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
